ReviewScreening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic
Under a Creative Commons license
open access
Graphical abstract
Keywords
COVID-19
Natural products
Antiviral
Clinical trials
Patent
Protection
Abbreviations
3CLpro
3C-like protease
ACE2
Angiotensin-converting enzyme 2
ARDS
Acute respiratory distress syndrome
CC50
Half maximal cytotoxic concentration
CD13
Human aminopeptidase N receptor
COVID-19
Corona virus disease 2019
DPP4
Dipeptidyl peptidase 4
Nsp3
Non-structural proteins proteases 3
EC50
Half maximal effective concentration
ER
Endoplasmic reticulum
EtOH
Ethanol
EtOAc
Ethyl acetate
FDA
Food and Drug Administration
HCoV-229E
Human coronavirus 229E
HCoV-HKU1
Human coronavirus Hong Kong University 1
HCoV-NL63
Human coronavirus NL63
HCoV-OC43
Human coronavirus OC43
HIV
Human immunodeficiency Virus
IC50
Half maximal inhibitory concentration
IL-6
Interleukin 6
IL-6R
Interleukin-6 receptor
MERS-CoV
Middle East Respiratory Syndrome Coronavirus
MHV-A59
Coronavirus Murine hepatitis virus
N
Unaltered natural product
ND
Natural product derivative
Nsp5
Non-structural proteins proteases 5
ORF1a/b
Nonstructural open‐reading frames
RdRp
RNA dependent RNA polymerase
RNA
Ribonucleic acid
SARS-CoV
Severe acute respiratory syndrome coronavirus
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
TEM
Transmission electron microscope
Cited by (0)
© 2021 The Authors. Published by Elsevier GmbH.